Hey there! Welcome!
Get updated on
stem cell
stem cell
stem cell
Top Picks

calendar
14 Jul, 26
dot
link
ESHRE 2026
Key highlights of the sessions on global and socio-cultural aspects of infertility presented at ESHRE from 5th to 8th July 2026 in London, UK.

calendar
14 Jul, 26
dot
link
ESHRE 2026
Key highlights of the sessions on fertility preservation presented at ESHRE from 5th to 8th July 2026 in London, UK.

calendar
27 Jul, 26
dot
link
Respir Med
  • Associations between relative muscle strength (RMS) and peak expiratory flow (PEF) in middle-aged and older adults were studied
  • Higher RMS was linked to better PEF, higher predicted PEF%, slower respiratory decline, and lower odds of impaired expiratory performance
  • Associations plateaued at RMS 1.8–2.0 and were stronger in males and smokers, supporting RMS as a simple marker of respiratory health during aging.

calendar
23 Jul, 26
dot
link
Diabetes Obes Metab.
  • In a prospective cohort (n=7633), early-pregnancy metabolically healthy & unhealthy overweight/obesity (MHO/MUO) were linked to higher fetal estimated weight (EFW) & abdominal circumference (AC) Z-scores at 28–36 wks & raised risk of EFW/AC overgrowth
  • MUO also raised the risk of head circumference (HC) undergrowth (OR 1.22)
  • MH normal weight (MUNW) was linked to lower HC Z-scores, partly mediated by GDM (11.2–16%)

calendar
23 Jul, 26
dot
link
J. Crit. Care.
  • Fluid creep and maintenance fluids are major contributors to ICU fluid burden.
  • Higher exposure was independently associated with major adverse kidney events within 30 days (MAKE30).
  • Increased risk extended to mortality, renal replacement therapy, and persistent renal dysfunction.
  • Reducing fluid creep may represent a modifiable target for ICU fluid stewardship.

calendar
23 Jul, 26
dot
link
Diabetes Res Clin Pr...
  • A meta-analysis of 22 RCTs (n=29,023) in adults with T2DM or overweight/obesity showed that tirzepatide significantly reduced major adverse cardiovascular events (MACE; OR:0.87) & all-cause mortality (OR:0.84)
  • The MACE odds lowered by 2.8% per 1 mg dose increase of tirzepatide, indicating a dose-response effect
  • No significant benefit was seen for individual MACE components or HF hospitalization.

calendar
24 Jul, 26